• Skip to Content
• Accessibility

• Give to CHOP
• Research
• For Healthcare Professionals
• Press Room
• Careers

• Health Information
  • Asthma
  • Fetal Conditions
  • Kids Health Galaxy
  • Injury Prevention
  • Pediatric Cancers
  • Pediatric Heart Conditions
  • Poison Prevention
  • Spina Bifida
  • Vaccine Education Center
• For Patients and Visitors
  • Directions, Maps and Parking
  • Before Your Visit
  • Type of Visit
  • Guide to Your Child’s Surgery
  • Hospital Amenities
  • Family Support and Resources
  • Visit or Contact a Patient
  • International Patient Services
  • Financial Matters
  • MyChart
• Specialties and Services
  • Airway Disorders
  • Asthma Program
  • Cancer Center
  • Cardiac Center
  • Congenital Hyperinsulinism Center
  • Fetal Diagnosis and Treatment
  • Gastroenterology, Hepatology
    and Nutrition
  • Neonatology
  • Orthopaedic Surgery
  • Transplant Center
  • Urology
  • All Specialties and Services
• Locations
  • Main Campus
  • Primary Care
  • Specialty Care
  • Community Hospital Partnerships
  • CHOP at Virtua
• Find a Doctor
• About Us
  • Best in the Nation
  • Our Philosophy of Care
  • Our Pediatric Network
  • HIPAA: Protecting Patient Privacy
  • CHOP in the Community
  • Social Media at CHOP
  • Quality and Performance
  • Volunteer Opportunities
  • Ethics and Compliance
  • Conflicts of Interest
• Search Results

• CHOP Home
• Find a Doctor
• Andrew C. Wood

Awards

2011, Translational Science Award, SIOP Annual Congress

2010, AACR Molecular Biology in Clinical Oncology Works

2009, Travel award to international workshop

2008, AMP Scholarship

2007, Child Cancer Foundation Professional Development Grant

2007, Genesis Oncology Trust, Professional Development Award

2007, Fulbright Scholarship – Ministry of Research, Science, and Technology Award

2006, Edward Roche Memorial Travel Grant

Original Papers

2011

Bresler SC, Wood AC, Haglund EA, Courtright J, Belcastro LT, Plegaria JS, et al. Differential inhibitor sensitivity of anaplastic lymphoma kinase variants found in neuroblastoma. Sci Transl Med 2011 Nov 9. Cited in PubMed; PMID: 22072639. Read the article

Cole KA, Huggins J, Laquaglia M, Hulderman CE, Russell MR, Bosse K, et al. RNAi screen of the protein kinome identifies checkpoint kinase 1 (CHK1) as a therapeutic target in neuroblastoma. Proc Natl Acad Sci U S A. 2011 Feb 22;108(8):3336-41. Cited in PubMed; PMID: 21289283. Read the article

2010

Balamuth NJ, Wood A, Wang Q, Jagannathan J, Mayes P, Zhang Z, et al. Serial transcriptome analysis and cross-species integration identifies centromere-associated protein E as a novel neuroblastoma target. Cancer Res. 2010 Mar 16. Cited in PubMed; PMID: 20233875. Read the article

2009

Mossé YP, Wood A, Maris JM. Inhibition of ALK signaling for cancer therapy. Clin Cancer Res. 2009 Sep 15;15 (18):5609-14. Cited in PubMed; PMID: 19737948. Read the article

Diskin SJ, Hou C, Glessner JT, Attiyeh EF, Laudenslager M, Bosse K, et al. Copy number variation at 1q21.1 associated with neuroblastoma. Nature. 2009 Jun 18;459 (7249):987-91. Cited in PubMed; PMCID: PMC2755253. Read the article

• Print
• Share

Awards and Honors

• Best in the Nation
• Magnet Award for Nursing Excellence

Legal

• Terms of Use
• Privacy Policy
• HIPAA: Protecting Patient Privacy

Short Cuts

• Cancer Center
• Cardiac Center
• Fetal Diagnosis and Treatment
• Pediatric Blood and Marrow Transplantation Program
• Site Map

• Our Philosophy of Care
• Directions, Maps and Parking
• Hospital Virtual Tour
• Guide to Your Child's Surgery
• Your Child's Bill

• Sign Up for Newsletters
• Social Media at CHOP
• Physician Referral Services
• Fellowships at The Children's Hospital of Philadelphia
• Continuing Medical Education

• © 1996-2013 The Children's Hospital of Philadelphia
  34th Street and Civic Center Boulevard
  Philadelphia, Pa. 19104
• Main Number: 215-590-1000
• Physician Referral Service: 1-800-879-2467
• Coordinates: 39.9486937, -75.1929596
•  
• An Equal Opportunity Employer
• The Children's Hospital of Philadelphia is an equal opportunity employer. We do not discriminate on the basis of race, color, gender, sexual orientation, age, religion, national or ethnic origin, disability or veteran status.